Article
Retatrutide: trial evidence and regulatory context
Retatrutide is a triple GIP, GLP-1 and glucagon receptor agonist studied for obesity and related conditions. A randomized phase 2 trial reported substantial weight change under controlled research conditions; gastrointestinal adverse events were common and varied with dose escalation. Phase 3 research has continued, including a cardiovascular and kidney outcomes trial. The FDA states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. Trial results must not be presented as permission for compounding, self-administration or clinical use.
This is the text in its original language.
Retatrutide: trial evidence and regulatory context
Retatrutide is a triple GIP, GLP-1 and glucagon receptor agonist studied for obesity and related conditions. A randomized phase 2 trial reported substantial weight change under controlled research conditions; gastrointestinal adverse events were common and varied with dose escalation. Phase 3 research has continued, including a cardiovascular and kidney outcomes trial. The FDA states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. Trial results must not be presented as permission for compounding, self-administration or clinical use.
Evidence identifiers
Informational content for research. This material is educational and intended for laboratory research contexts. It is not medical advice, a prescription, a clinical protocol, or a guarantee of outcome.